In the BioHarmony Drug Report Database
Ixempra (ixabepilone) is a small molecule pharmaceutical. Ixabepilone was first approved as Ixempra on 2007-10-16. It is used to treat breast neoplasms in the USA. The pharmaceutical is active against tubulin beta chain. In addition, it is known to target tubulin–tyrosine ligase. Ixempra’s patents are valid until 2024-08-21 (FDA).
Image (chem structure or protein)